

Press Release May 4, 2017

Infant Bacterial Therapeutics AB (publ) Interim Management Statement, January 1 – March 31, 2017

Message from the CEO

IBT's operations will during the current year be focused on completion of the ongoing Phase II study and planning of the following clinical Phase III study of IBP-9414. As previously stated, a Phase III study will require additional capital. IBT is actively working with several potential financing possibilities and is seeking partners who can contribute resources for the continuing development program. We expect to gain improved understanding how agencies and experts view our new project IBP-1016, we also expect to receive our Phase II results of IBP-9414 (NCT02472769), and plan to apply for the main marketplace, Nasdaq Stockholm.

Staffan Strömberg
CEO

Financial summary

SEK 000's	2017 Jan-Mar	2016 Jan-Mar	2016 Jan-Dec
Total comprehensive income	117	-	162
Operating profit/loss	-8 563	-5 103	-38 090
Result after tax	-8 563	-5 165	-38 106
Total assets	100 925	55 593	110 109
Cash flow for the period	-9 113	-6 782	49 375
Cash	84 673	37 629	93 786
Earnings per share, weighted average, before and after dilution (SEK)	-1,56	-2,82	-8,42
Equity per share (SEK)	17,56	26,73	19,12
Equity ratio (%)	96%	91%	96%

Significant events during the first quarter 2017

- In January 2017, all 120 patients were included in the Company's phase II clinical trial in IBP-9414 (NCT02472769)
- IBT's series B shares were listed on Nasdaq First North Premier on March 14

Significant events after the reporting period

- No significant events have occurred after the reporting period

Press Release May 4, 2017

Infant Bacterial Therapeutics AB (publ) Interim Report is now available on the companies website www.ibtherapeutics.com.

About Infant Bacterial Therapeutics AB

Infant Bacterial Therapeutics AB (publ) ("IBT") is a pharmaceutical company with a vision to develop drugs influencing the human infant microbiome, and thereby prevent or treat rare diseases affecting premature infants. Using its extensive experience in live bacterial therapeutics and its well-developed knowledge of the action of *Lactobacillus reuteri*, IBT is developing its lead drug candidate IBP-9414, to prevent necrotizing enterocolitis ("NEC"), a fatal, rare disease that afflicts premature infants. The FDA and the European Commission have granted IBT Orphan Drug Designation, and the FDA have granted Rare Pediatric Disease Designation for IBP-9414 for the prevention of NEC.

IBT is further pursuing a second rare disease programme IBP-1016 for the treatment of an unmet medical need in gastroschisis, a severe disease in infants. By developing these drugs, IBT has the potential to fulfil unmet needs for diseases where there are currently no prevention or treatment therapies available.

IBT is listed on Nasdaq First North Premier with Erik Penser Bank as Certified Adviser. www.ibtherapeutics.com

For additional information please contact

Staffan Strömberg, CEO
Infant Bacterial Therapeutics AB
Bryggargatan 10
111 21 Stockholm
Phone: +46 8 410 145 55
info@ibtherapeutics.com
www.ibtherapeutics.com

Publication

This information is information that Infant Bacterial Therapeutics AB is obliged to make public pursuant to the EU Market Abuse Regulation and which is to be made public according to the Nasdaq regulations for companies listed on Nasdaq First North. The information was submitted for publication, through the agency of the contact person set out above, at 12.00 CET on May 4, 2017.